The health of blood vessels may be the single most consequential biological variable governing how well—and how long—people age. A comprehensive review in Circulation reframes vascular aging not as an inevitable backdrop to cardiovascular disease, but as an active, mechanistically targetable process that shapes organ decline across the entire body. This perspective shift has direct implications for how longevity medicine prioritizes interventions.
The review synthesizes evidence across seven canonical hallmarks of vascular aging: cellular senescence, chronic sterile inflammation, loss of proteostasis, mitochondrial dysfunction, genomic instability, epigenetic remodeling, and stem cell exhaustion. Critically, it argues these processes are not generic aging mechanisms playing out in vessels—they interact with the vasculature's distinctive mechanical load and metabolic demands to generate organ-specific pathological signatures. Arterial stiffening, compromised endothelial barrier function, and dysregulated vasomotor tone emerge as the downstream phenotypes linking molecular aging to systemic risk. Advances in single-cell omics and cross-organ molecular clocks have further revealed striking heterogeneity: different vascular beds age at different rates and via partially distinct mechanisms, undermining one-size-fits-all treatment models.
What makes this review particularly noteworthy is its translational inventory. Senolytic agents capable of clearing senescent vascular cells, immune-mediated clearance strategies, and mitochondrial-targeted interventions are all assessed as viable therapeutic directions, placing vascular biology at the intersection of geroscience and precision medicine. The proposed use of multimodal biomarkers—combining epigenetic clocks, proteomic signatures, and imaging—to stage individual vascular age is an approach gaining traction in clinical trial design. As a narrative review rather than a meta-analysis, causal conclusions remain constrained, and most cited interventions are preclinical or early-phase. Nevertheless, for researchers and clinicians, this consolidation in a top-tier cardiovascular journal signals that vascular aging has crossed from theoretical framework into actionable scientific priority.
